Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (referred to in the metadata as Harrow, Inc.) on September 23, 2015. The report details a material definitive agreement entered into by the Company's wholly-owned subsidiary, ImprimisRx PA, Inc.
Key Financial Metrics
The filing discloses a specific transaction value but does not provide broader financial statements such as revenue, profit, cash flow, or debt levels.
- Transaction Value: Approximately $499,000 in cash.
- Payment Terms: To be paid at closing.
- Other Metrics: The filing text does not provide clear values for revenue, margins, liquidity, or debt.
Material Changes
The primary material change is the entry into an Asset Purchase Agreement to acquire substantially all assets of several entities (collectively the "Sellers"), including Topical Apothecary Group, LLC, Aerosol Science Laboratories, Inc., SinuTopic, Inc., and Mycotoxins, LLC. The assets include intellectual property, trademarks, inventories, equipment, customer lists, and permits. The Company will assume certain limited liabilities.
Outlook, Risks, and Management Commentary
Management includes a cautionary note regarding forward-looking statements. Key risks and contingencies identified include:
- Possibility that the transaction closing may be delayed or may not occur.
- Difficulties with the integration process or realizing expected benefits.
- General regulatory developments impacting compounding pharmacies, outsourcing facilities, and the pharmaceutical industry.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $499,000 cash payment.
- Confirm the specific "limited liabilities" assumed by the Company in the transaction.
- Monitor regulatory developments affecting compounding pharmacies that could impact the acquired assets.
- Review subsequent filings for integration progress or delays.